By Joseph Burns, from the Volume XXV, No. 2 – January 22, 2018 issue
THERE IS ALREADY A SHORTAGE of competent professionals available to sign off on medical laboratory reports in India. Now a recent Supreme Court decision may exacerbate this problem.
On Jan. 11, the Hindu Business Line, a newspaper, reported that medical labs across India could face a significant shortage of competent professionals to sign lab reports after
By Joseph Burns, from the Volume XXIV, No. 1 – January 9, 2017 issue
CEO SUMMARY: Among the three chief reasons for the merger of CellNetix and Puget Sound Institute of Pathology, the most compelling was the need to address the challenges in the current reimbursement environment and to prepare for reductions in payment to pathologists expected in the coming years under the Patient Access to Medicare Act. CellNetix
By Joseph Burns, from the Volume XXIII No. 17 – December 19, 2016 issue
CEO SUMMARY: In the United States, medical labs have long recognized that paying over-market rates to lease phlebotomy space in physicians’ officers is an inducement and a violation of federal anti-kickback laws. In Australia, a law in 2010 that removed the cap on what labs could pay to lease phlebotomy space in physicians’ offices caused
By Robert Michel, from the Volume XXIII, No. 16 - November 28, 2016 issue
In recent weeks, two different lab transactions were announced. One involved a hospital laboratory management contract and the other was a potential merger of two anatomic pathology lab companies. The first announcement came on October 31, when Lovelace Health System of Albuquerque, New Mexico, released news that it entered into an “inpatient and outpatient laboratory
By Robert Michel, from the Volume XXII NO. 5 - March 30, 2015 issue
BOTH OF THE NATION’S LARGEST clinical laboratory companies reported increased specimen volume as a result of the Accountable Care Act (ACA), as noted in their respective fourth quarter and full-year earnings reports.
By Joseph Burns, from the Volume XXII NO. 4 - March 9, 2015 issue
CEO SUMMARY: PerkinElmer is the latest U.S. organization to open a clinical laboratory business in China. Last December, it formally opened its new Suzhou PerkinElmer Medical Laboratory. The new lab is located about 60 kilometers (37 miles) west of Shanghai. It will provide neonatal and prenatal screening along with infectious disease testing. PE’s new venture hopes to leverage relationships developed from providing newborn and prenatal screening in China throughout for the past 20 years.
By Robert Michel, from the Volume XXI NO. 7 – May 19, 2014 issue
How about a hospital that doesn’t have a medical laboratory but issues lab test reports to patients? This unusual development happened in India recently. The Free Press Journal of Mumbai, India, reported earlier this month that government health officials had conducted a surprise inspection of the City Hospital at MP Nagar, Bhopal. Inspectors found that,
By Robert Michel, from the Volume XXI NO. 3 - February 24, 2014 issue
IN DECIDING TO PURSUE ACCREDITATION TO ISO 15189: Medical Laboratories, Caris Life Sciences considered the international benefits of this designation.
It was December when Caris Life Sciences of Irving, Texas, announced that it had earned accreditation to ISO 15189 from the American Association for Laboratory Accreditation (A2LA). In addition to genomic testing, the company runs Caris
By Robert Michel, from the Volume XX No. 15 - November 11, 2013 issue
CEO SUMMARY: Professional investors are smart with their money. Thus, it is no surprise that clinical lab and pathology companies owned by private equity firms are the first to be sold or closed. These investors are acting in response to the cumulative negative financial impact of recent cuts to lab test prices. Even more worrisome
By Robert Michel, from the Volume XX No. 1 - January 22, 2013 issue
WILL HISTORY LOOK BACK ON 2013 AND DECLARE IT to have been a watershed year for the clinical laboratory testing industry? I ask that question because many of you are telling us here at THE DARK REPORT that you expect rapid and unprecedented changes in the lab testing marketplace in your community or region.
In my
